HERON THERAPEUTICS, INC. /DE/ financial data

Symbol
HRTX on Nasdaq
Location
San Diego, CA
Fiscal year end
31 December
Latest financial report
10-K - Q4 2025 - 26 Feb 2026

Key Ratios

Label TTM Value / Value Unit Change %
Current Ratio 167% % -29%
Quick Ratio 55% % -0.95%
Debt-to-equity -3771% % -430%
Return On Equity 305% % 716%
Return On Assets -8.3% % -36%

Shares

Label TTM Value / Value Unit Change %
Entity Common Stock, Shares Outstanding 188,537,136 shares 24%
Common Stock, Shares, Outstanding 188,314,430 shares 24%
Entity Public Float $235,100,000 USD -40%
Common Stock, Value, Issued $1,883,000 USD 24%
Weighted Average Number of Shares Outstanding, Basic 166,707,000 shares 9.4%
Weighted Average Number of Shares Outstanding, Diluted 166,707,000 shares 9.4%

Income Statement

Label TTM Value / Value Unit Change %
Research and Development Expense $12,429,000 USD -25%
Selling and Marketing Expense $49,061,000 USD 4.2%
General and Administrative Expense $54,605,000 USD 2.3%
Costs and Expenses $116,095,000 USD -0.91%
Operating Income (Loss) $2,538,000 USD 78%
Net Income (Loss) Attributable to Parent $20,195,000 USD -49%
Earnings Per Share, Basic -0.12 USD/shares -33%
Earnings Per Share, Diluted -0.12 USD/shares -33%

Balance Sheet

Label TTM Value / Value Unit Change %
Cash and Cash Equivalents, at Carrying Value $28,647,000 USD 11%
Cash, Cash Equivalents, and Short-term Investments $46,600,000 USD -21%
Accounts Receivable, after Allowance for Credit Loss, Current $89,587,000 USD 14%
Inventory, Net $92,746,000 USD 74%
Assets, Current $238,066,000 USD 14%
Property, Plant and Equipment, Net $12,403,000 USD -17%
Operating Lease, Right-of-Use Asset $0 USD -100%
Other Assets, Noncurrent $5,408,000 USD -17%
Assets $255,877,000 USD 9.7%
Accounts Payable, Current $8,994,000 USD -23%
Employee-related Liabilities, Current $9,270,000 USD -3%
Liabilities, Current $96,098,000 USD 5.1%
Operating Lease, Liability, Noncurrent $522,000 USD -85%
Other Liabilities, Noncurrent $4,808,000 USD 682%
Liabilities $241,544,000 USD -9.5%
Accumulated Other Comprehensive Income (Loss), Net of Tax $4,000 USD -69%
Retained Earnings (Accumulated Deficit) $1,939,789,000 USD -1.1%
Stockholders' Equity Attributable to Parent $14,333,000 USD
Liabilities and Equity $255,877,000 USD 9.7%

Popular Metrics

Label TTM Value / Value Unit Change %
Net Cash Provided by (Used in) Operating Activities $8,870,000 USD 6.8%
Net Cash Provided by (Used in) Financing Activities $64,000 USD
Net Cash Provided by (Used in) Investing Activities $2,273,000 USD 78%
Common Stock, Shares Authorized 400,000,000 shares 0%
Common Stock, Shares, Issued 188,314,430 shares 24%
Common Stock, Par or Stated Value Per Share 0.01 USD/shares 0%
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect $6,533,000 USD 21%
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents $28,647,000 USD 11%
Interest Paid, Excluding Capitalized Interest, Operating Activities $636,000 USD -2%
Deferred Tax Assets, Valuation Allowance $414,999,000 USD -0.98%
Deferred Tax Assets, Gross $414,999,000 USD -1.1%
Operating Lease, Liability $780,000 USD -79%
Payments to Acquire Property, Plant, and Equipment $109,000 USD
Comprehensive Income (Loss), Net of Tax, Attributable to Parent $20,204,000 USD -49%
Lessee, Operating Lease, Liability, to be Paid $3,138,000 USD -50%
Property, Plant and Equipment, Gross $25,283,000 USD -23%
Operating Lease, Liability, Current $0 USD -100%
Lessee, Operating Lease, Liability, to be Paid, Year One $3,138,000 USD -0.48%
Lessee, Operating Lease, Liability, Undiscounted Excess Amount $5,000 USD -97%
Deferred Tax Assets, Operating Loss Carryforwards $329,398,000 USD 1.6%
Preferred Stock, Shares Issued 70,012 shares
Preferred Stock, Shares Authorized 2,500,000 shares 0%
Unrecognized Tax Benefits $10,903,000 USD 0%
Additional Paid in Capital $1,951,185,000 USD 3.5%
Preferred Stock, Shares Outstanding 70,012 shares
Depreciation, Depletion and Amortization $551,000 USD -20%
Share-based Payment Arrangement, Expense $10,339,000 USD -20%
Preferred Stock, Par or Stated Value Per Share 0.01 USD/shares 0%